MK-8245 trifluoroacetate Catalog No.:M10457-2 3-thiazol-5-yl)formamido]propanamido]-N-[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]propanamide

3-thiazol-5-yl)formamido]propanamido]-N-[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]propanamide

3-difluorophenyl)-5H

Characterization of primate bronchoalveolar mast cells

1206711-16-1

Smiles: COC1C=C(CCC(O)CC(O)CCC2C=C(OC)C(O)=CC=2)C=CC=1O

MK-8245 trifluoroacetate Catalog No.:M10457-2 3-thiazol-5-yl)formamido]propanamido]-N-[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]propanamideMK 8245 is a potent, liver targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window. MK 8245 was believed to inhibit the SCD enzyme solely in the liver and not in other tissues for the following reasons. When SCD inhibition has been measured by desaturation index in tissues of rodents treated with MK 8245, the desaturation index was significantly reduced in liver but not in